From Surf Wiki (app.surf) — the open knowledge base
Camrelizumab
Camrelizumab (INN; development code SHR-1210) is an anti-PD-1 immune checkpoint inhibitor that is being investigated for hepatocellular carcinoma and Hodgkin lymphoma. PD-1 is programmed cell death protein 1.
Rendering article…
Content sourced from manual.
This content may have been generated or modified by AI, and may be sourced from third parties. CloudSurf Software LLC makes no warranties as to its accuracy, completeness, or reliability, and accepts no liability for it. Always verify important information against primary sources.
Report